Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Here we reported novel apigenin-rivastigmine hybrids were rationally designed and synthesized by the multi-target-directed ligands (MTDLs) strategy, their activity in vitro results revealed that compound 3d showed significant antioxidant potency (ORAC = 1.3 eq), and it was a reversible huAChE (IC50 = 6.8 μM) and huBChE (IC50 = 16.1 μM) inhibitor. 3d also served as a selective metal chelator, and it significantly inhibited and disaggregated self-mediated and Cu2+-mediated Aβ1-42 aggregation, and also inhibited hAChE-mediated induced Aβ1-40 aggregation. Compound 3d exhibited remarkable neuroprotective effect and hepatoprotective activity. In addition, compound 3d presented favourable blood-brain barrier penetration in vitro and drug-like property. Further, the in vivo assay displayed that 3d indicated remarkable dyskinesia recovery rate and response efficiency on AD zebrafish, and exhibited surprising protective effect on Aβ1-40-mediated zebrafish vascular injury. More importantly, 3d did not indicate obvious acute toxicity at dose up to 2000 mg/kg, and could improve scopolamine-induced memory impairment. Subsequently, the regulation of multi-targets for 3d were further confirmed through transcriptome sequencing of brain hippocampi, which also offered novel potential targets and opened a new way to treat Alzheimer's disease. More interestingly, the metabolism of 3din vitro indicated that 4 metabolites in rat liver microsome metabolism, 2 metabolites in human liver microsome metabolism, and 4 metabolites in intestinal flora metabolism, which offered supports for the preclinical study of 3d. Overall, this study exhibited that compound 3d was a promising advanced compound targeted multiple factors associated with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506
Marzi, S. J., Leung, S. K., Ribarska, T., Hannon, E., Smith, A. R., Pishva, E., Poschmann, J., Moore, K., Troakes, C., Al-Sarraj, S., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0253-7 · Cited by 232
A Genomewide Screen for Late-Onset Alzheimer Disease in a Genetically Isolated Dutch Population
Liu, F., Arias-Vásquez, A., Sleegers, K., Aulchenko, Y. S., Kayser, M., Sanchez-Juan, P., Feng, B.-J., Bertoli-Avella, A. M., van Swieten, J., Axenovich, T. I., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/518720 · Cited by 156
Qiang, X., Sang, Z., Yuan, W., Li, Y., Liu, Q., Bai, P., Shi, Y., Ang, W., Tan, Z., & Deng, Y. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.045 · Cited by 113
Self-citationWang, Z., Hu, J., Yang, X., Feng, X., Li, X., Huang, L., & Chan, A. S. C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01417 · Cited by 91
Del Prete, D., Rice, R. C., Rajadhyaksha, A. M., & D'Adamio, L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.733626 · Cited by 86
Be open about drug failures to speed up research
Alteri, E., & Guizzaro, L. (2018) · Nature · doi:10.1038/d41586-018-07352-7 · Cited by 50
Cited by
Role of natural products for the treatment of Alzheimer’s disease
Noori, T., Dehpour, A. R., Sureda, A., Sobarzo-Sanchez, E., & Shirooie, S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173974 · Cited by 141
Vicente-Zurdo, D., Rosales-Conrado, N., León-González, M. E., Brunetti, L., Piemontese, L., Pereira-Santos, A. R., Cardoso, S. M., Madrid, Y., Chaves, S., & Santos, M. A. (2022) · Biomedicines · doi:10.3390/biomedicines10071510 · Cited by 47
“, tacrine, donepezil), only a very few have enclosed the pharmacophoric moiety of the drug inhibitor of both ChEs (rivastigmine) [33,40,41].”
BackgroundMolecular mechanisms of Alzheimer’s disease: From therapeutic targets to promising drugs
Alan, E., Kerry, Z., & Sevin, G. (2023) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.12861 · Cited by 17
“The 3d, one of these hybrids, has been reported to be a multitarget drug candidate that targets many factors in the pathophysiology of AD with its antioxidant, acetylcholinesterase, and butyrylcholinesterase inhibitor; Cu-mediated Aβ1-42 aggregation inhibitor; and neuroprotective effects.(141) Combined administration…”
Background
Metadata
- Authors
- Sang, Z., Wang, K., Shi, J., Cheng, X., Zhu, G., Wei, R., Ma, Q., Yu, L., Zhao, Y., Tan, Z., & Liu, W.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 187
- Pages
- 111958
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2995361161
- Cited by
- 97
- References
- 11
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.